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Abstract
Background: One of the criteria to objectively prioritize merozoite antigens for malaria vaccine development is the
demonstration that naturally acquired antibodies are associated with protection from malaria. However, published evidence
of the protective effect of these antibodies is conflicting.
Methods and Findings: We performed a systematic review with meta-analysis of prospective cohort studies examining the
association between anti-merozoite immunoglobin (Ig) G responses and incidence of Plasmodium falciparum malaria. Two
independent researchers searched six databases and identified 33 studies that met predefined inclusion and quality criteria,
including a rigorous definition of symptomatic malaria. We found that only five studies were performed outside sub-
Saharan Africa and that there was a deficiency in studies investigating antibodies to leading vaccine candidates merozoite
surface protein (MSP)-142 and erythrocyte binding antigen (EBA)-175. Meta-analyses of most-studied antigens were
conducted to obtain summary estimates of the association between antibodies and incidence of P. falciparum malaria. The
largest effect was observed with IgG to MSP-3 C terminus and MSP-119 (responders versus nonresponders, 54%, 95%
confidence interval [CI] [33%–68%] and 18% [4%–30%] relative reduction in risk, respectively) and there was evidence of a
dose-response relationship. A tendency towards protective risk ratios (RR,1) was also observed for individual study
estimates for apical membrane antigen (AMA)-1 and glutamate-rich protein (GLURP)-R0. Pooled estimates showed limited
evidence of a protective effect for antibodies to MSP-1 N-terminal regions or MSP-1-EGF (epidermal growth factor-like
modules). There was no significant evidence for the protective effect for MSP-2 (responders versus nonresponders pooled
RR, MSP-2FC27 0.82, 95% CI 0.62–1.08, p=0.16 and MSP-23D7 0.92, 95% CI 0.75–1.13, p=0.43). Heterogeneity, in terms of
clinical and methodological diversity between studies, was an important issue in the meta-analysis of IgG responses to
merozoite antigens.
Conclusions: These findings are valuable for advancing vaccine development by providing evidence supporting merozoite
antigens as targets of protective immunity in humans, and to help identify antigens that confer protection from malaria.
Further prospective cohort studies that include a larger number of lead antigens and populations outside Africa are greatly
needed to ensure generalizability of results. The reporting of results needs to be standardized to maximize comparability of
studies. We therefore propose a set of guidelines to facilitate the uniform reporting of malaria immuno-epidemiology
observational studies.
Please see later in the article for the Editors’ Summary.
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Malaria caused by Plasmodium falciparum is a leading cause of
mortality and morbidity globally, particularly among young
children. After repeated exposure, individuals develop effective
immunity that controls blood-stage parasitaemia, thereby reducing
clinical symptoms and life-threatening complications (reviewed in
[1]). Antibodies are important mediators of acquired immunity to
malaria as evidenced by experimental animal models and, most
importantly, passive transfer studies in which antibodies from
malaria-immune adults were successfully used to treat patients
with severe malaria [2,3]. Antibodies to merozoite antigens are
considered important targets of protective antibodies and are
thought to function in vivo by inhibiting merozoite invasion of
erythrocytes, opsonizing merozoites for phagocytosis, and anti-
body-dependent cellular inhibition [4–7]. However, it is unclear
which merozoite antigens are important targets of naturally
acquired immunity.
A number of merozoite antigens have established roles in
erythrocyte invasion and some have been identified as targets of
human invasion-inhibition antibodies or antibody-dependent
cellular inhibition in vitro [8–15]. Merozoite surface proteins
(MSPs) are thought to be involved in the initial attachment of the
merozoite to the erythrocyte surface (e.g., MSP-1) and apical
membrane antigen-1 (AMA-1) has been implicated in apical
reorientation of the merozoite prior to invasion. Two invasion
ligand families present in the apical organelles, the erythrocyte
binding antigens (e.g., EBA175, EBA181, EBA140) and P.
falciparum reticulocyte-binding homologues are also required for
invasion [16]. There are numerous surface proteins with no known
function including MSP-2, MSP-3, MSP-4, and glutamate-rich
protein (GLURP) [16]. Genetic polymorphisms exist in most
antigens and some can be grouped into major allelic types. Many
of these antigens are currently being evaluated or developed as
candidates for inclusion in an erythrocytic-stage malaria vaccine
[17].
There are several criteria that can be used to objectively
prioritize known and predicted antigens for vaccine development
[17]. These include the demonstration that antibodies against
these antigens inhibit P. falciparum growth in vitro, or are protective
in animal models, and the demonstration that naturally acquired
antibodies are associated with protection from symptomatic
disease in malaria endemic populations. Consequently, numerous
epidemiological studies have investigated the role of merozoite
surface antigens as targets of human immunity. However, the
epidemiological evidence of the protective effect of naturally
acquired anti-merozoite responses is conflicting. There are
numerous potential reasons for the inconsistencies in the estimates
of protection. In malaria endemic areas the rate at which natural
immunity develops is dependent on the intensity and stability of
exposure to P. falciparum, with immunity to severe and mild disease
developing more rapidly in areas with higher transmission [1,18].
Differences in the acquisition of immunity may influence
associations between specific responses and immunity. Further-
more, the prevalence of the major allelic types of specific antigens
and subsequent acquisition of allele-specific immunity may be
different across populations. The alleles represented in recombi-
nant proteins used for determining antibody responses varies
between studies in addition to the preparation of antigens used in
immunoassays. Most importantly, the study designs used to
investigate the associations between antibody responses and P.
falciparum malaria studies vary considerably among the published
literature. Evidence quoted in the literature regarding the
protective role of antigen-specific antibodies is often based on
data from cross-sectional or case-control studies. Examining the
association of antibody responses with parasitological and clinical
outcomes determined at a single time point, or in individuals who
have already developed disease, makes the establishment of
causality problematic. The highest level of evidence of causality
in observational studies comes from prospective cohort studies in
which a temporal relationship can be established between
exposure and outcome.
We performed a systematic review, with meta-analyses, of
cohort studies to determine the association of antibody responses
to merozoite surface antigens with incidence of P. falciparum
malaria in naturally exposed populations, and to identify factors
that may account for differences in reported findings. The broad
aim of this study was to advance our understanding of naturally
acquired immunity to malaria and to contribute to rational
vaccine development.
Materials and Methods
We performed a systematic review of the published literature
according to the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) guidelines for the conduct of meta-
analyses of observational studies [19]. Results are reported
according to the recently published PRISMA guidelines (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses;
http://www.prisma-statement.org; Text S1). The study protocol
was developed by FJIF, JAS, and JGB.
Search Methods for Identification of Studies
PubMed, Web of Science, Scopus, Google Scholar, African
Index Medicus, and LILACS (Latin American and Caribbean
Health Sciences Literature) (all years, ending 31 January 2009)
were searched for studies examining the association of antibody
responses to merozoite antigens with P. falciparum malaria. Key
words included: MSP, merozoite surface protein, MSA, merozoite
surface antigen, GLURP, glutamate-rich protein, serine repeat
antigen, SERA, S-Antigen, ABRA, AMA, apical membrane
antigen, EBA, erythrocyte binding antigen, rhoptry, malaria, P.
falciparum, immunity, antibodies, IgG, cohort, longitudinal,
incidence, risk, epidemiology, vaccine. The key words variant
surface antigen (VSA) were also used because merozoite antigens
are sometimes used as comparative antigens in studies investigat-
ing VSAs. The reference lists of obtained papers were searched for
further studies. Studies reported in languages other than English
were included.
Criteria for Considering Studies for This Review
Study designs. The criteria for inclusion of studies were
population-based prospective studies and population-based
treatment to reinfection studies. Population-based cross-sectional
studies to determine prevalence were excluded because causality
cannot be established. Case-control studies, hospital-based studies,
and vaccine efficacy trials of blood-stage vaccines were also
excluded because of the rigorous inclusion and exclusion criteria
applied during these studies, such that the participants would not
be representative of the general population.
Study participants. The criterion for inclusion of
participants was individuals living in malaria endemic areas.
Studies restricted to pregnant women and/or children ,1y
(including maternal transfer studies) were excluded to remove the
confounding effect of maternal transferred immunity. Studies
where individuals were selected according to their P. falciparum
status and studies investigating returned travellers or transmigrants
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general population.
Antibody measures. Total immunoglobulin G (IgG)
responses to recombinant or synthetic defined merozoite
antigens measured at baseline (i.e., time 0) were considered. IgG
responses to full length proteins, processing products, and defined
regions of merozoite antigens were included, but IgG responses to
peptides that represent undefined regions or incomplete domains
or subdomains of antigens were excluded.
Malaria outcome measures. The following malaria
outcome measures during follow-up were included: high density
P. falciparum infection ($5,000/ml), symptomatic P. falciparum
malaria, severe P. falciparum malaria, and P. falciparum malaria-
associated mortality. In treatment-to-reinfection studies P.
falciparum reinfection was also included as an outcome. Newly
established blood-stage infection must have been differentiated
from treatment failure by either PCR or documented clearance of
infection within a specified time frame appropriate for the chosen
antimalarial.
Quality criteria. The minimum quality criteria for inclusion
in the review were that: detection of malaria was by active case
detection (ACD) and/or passive case detection (PCD);
parasitaemia was confirmed by slide microscopy, rapid detection
kit, or PCR; symptomatic malaria was defined as fever and/or
history of fever (within the past 72 h) plus a high density
parasitaemia threshold (to increase specificity because low-grade
parasitaemia is common in most settings); severe malaria was
defined by the World Health Organization criteria and other
causes of morbidity excluded; and other common causes of
mortality excluded before a diagnosis of malaria-associated
mortality [20,21].
Selection of Studies
Review authors (FJIF, JSR, and JGB) identified possible studies,
FJIF and JSR assessed the methodological quality of included
studies independently, with discrepancies resolved by discussion
with JGB.
Effort to include all available studies and data. Authors
of studies that had defined a case of symptomatic malaria as fever
and/or history of fever plus a P. falciparum parasitaemia of any
density (i.e., did not meet quality criteria of fever plus a high
density threshold) were invited to provide estimates or data
meeting the quality criteria. Some studies had analysed antibody
levels at baseline as the outcome variable, comparing baseline
levels in those who had or did not have P. falciparum malaria during
follow-up. For these studies, data was extracted and reanalysed so
that malaria was the outcome variable and related to antibodies at
baseline. If the raw data were not presented, authors of the study
were invited to reanalyse or provide data for the inclusion of their
study in the systematic review. In addition, we contacted several
authors whose studies did not meet the inclusion criteria yet
contained data that were eligible for the systematic review. These
were the authors of studies that had measured antibody responses
after baseline (i.e., examined the association of antibody responses
with malaria cases diagnosed both retrospectively and
prospectively) and invited them to provide estimates or data
concerning prospective P. falciparum incidence only. We also
contacted authors who had restricted analysis to individuals who
were parasite positive at baseline and invited them to provide
estimates or data on the whole cohort where possible. If authors
were unable to provide estimates or data, the study was classified
as not meeting inclusion and/or quality criteria and excluded from
the systematic review.
Data Analysis
Data collection. Measures of association (odds ratios [ORs],
risk ratios [RRs], incidence rate ratios [IRRs], or hazard ratios
[HRs]) and their 95% confidence intervals (CIs) were extracted or
derived using data reported in the publications. Data extraction
was performed independently by FJIF and JSR, using proforma
designed by FJIF, JAS, and JGB. The investigators of the original
studies were contacted if relevant information on eligibility or key
study data were not available in the published report. An email
was sent to authors explaining the nature of the systematic review
and the information required together with proforma. If the
author did not respond within three email attempts then no further
action was taken. Where a study does not provide measures of
association (or they could not be calculated with the information
provided), the study results will be described only in narrative
terms.
Standardization of antibody measures. A major issue in
reviewing the published results of different epidemiologic studies
examining the relation between an exposure variable and risk of
the outcome is that the results are presented in many different
ways. Determining antibody levels by enzyme-linked
immunosorbent assay (ELISA) does not produce a common
metric measurement among studies. Individuals can be classified
as ‘‘responders’’ or ‘‘nonresponders’’ relative to a negative control
(unexposed sera) within each study. Study-specific comparisons of
these exposure variables can then be pooled. However, categories
based on arbitrary cut-offs (including categories of responders
based on statistical rankings) cannot be pooled across studies.
For studies where the antibody measures were analysed as
continuous exposure variables we either asked the authors to
reanalyse their data by collapsing the antibody data into categories
or asked them to provide the standard deviation of the data so we
could calibrate the estimate to represent the relative change in the
risk of malaria associated with a change of one standard deviation
of the antibody level. For log transformed antibody data we used
log base 2 so that the relative change in malaria risk corresponds to
a doubling of antibody level.
Standardization of malaria outcome measures. ORs
considerably overestimate the RR, if the incidence risk is .20%,
which is often the case in highly malaria endemic areas [22]. Thus,
RR, HR, and IRR were extracted or calculated where possible, or
unadjusted ORs were converted to RR using the method of Zhang
and Yu [23]. RR, HR, and IRR are hereinafter denoted as RR. A
RR equal to 1 occurs when the incidence risk of malaria is equal
for those with antibody responses (responders) and those without
(nonresponders), and when the incidence risk is unchanged for 2-
fold increases in the antibody levels. Where possible, estimates
adjusted for demographic variables, spatial confounders, P.
falciparum parasitaemia (at baseline or preseason), and/or bed net
use are reported. Estimates adjusted for other anti-merozoite
antibodies (including antibodies to schizont protein extract) are not
reported because antibody responses are typically highly
correlated making it difficult to estimate their individual
regression coefficients reliably; in these cases unadjusted
estimates are reported. For all malaria outcomes the study-
assigned P. falciparum definitions were used.
Our aim was to obtain a single RR estimate for each study. If
antibody responses to the same antigen, in the same population-
based study, were reported in several publications, results from the
largest sample size were used. Separate estimates were obtained
for the RR associated with AMA-1 (full-length ectodomains of
FVO [pro-DI-DII-DIII] and 3D7 [DI-DII-DIII]), EBA-175 (all
regions including F1 and F2), GLURP (R0, R1, and R2
fragments), MSP-2 (full length 3D7, full length FC27, and C
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conserved C terminus). For MSP-1, separate analyses were done
for each region and allelic type (MSP-1-block 1 [MAD20], MSP-
1-block 2 [K1-like (3D7), MAD20-like [MAD20], and RO33-like
[RO33]), and processing fragments (MSP-142, MSP-119 [including
MSP-1-EGF1, MSP-1-EGF2]). Estimates from the above-men-
tioned regions/alleles were used to ensure maximum comparabil-
ity between studies. Separate analyses were not done for MSP-3-
Ct or MSP-119 alleles because of the conserved nature of MSP-3-
Ct and MSP-119 (similarly EGF domains). For these antigens, if
responses to multiple alleles were investigated in the same study,
the most common circulating allele in the population was included
in the meta-analysis.
Meta-analysis. Where there were sufficient data, a pooled
summary statistic for each malaria outcome was calculated using
either a fixed-effect or random-effects model. The standard error
of the natural logarithm (ln) of the RR was calculated using the
formula (ln[upper limit of CI]2ln[RR])/1.96. Heterogeneity
between studies was tested with the I
2 statistic [24]. If the I
2
statistic was #30%, a meta-analysis based on a fixed-effect model
was conducted; otherwise the random-effects model was used.
When the I
2 statistic was .75% and/or the lower 95% confidence
limit was between 50%–100%, the studies were not combined
[25]. When statistical heterogeneity was noted it was evaluated by
fitting meta-regression models to the log-transformed individual
study RRs.
Clinical and methodological heterogeneity was explored using
prespecified variables to minimize spurious findings. Variables
evaluated included study design (prospective cohort, treatment-to-
reinfection), length of follow-up, age of study participants
(dichotomous variable: adults and children, children only), malaria
endemicity (perennial, seasonal, perennial with seasonal peaks),
source of malaria cases (dichotomous variable: ACD only, PCD,
and ACD), definition of symptomatic malaria, preparation of
antigen (allele, expression vector, tag), and method of antibody
determination (ELISA, microarray). Influence analysis was also
performed whereby pooled estimates were calculated omitting one
study at a time. Where possible, publication bias was assessed
visually by plotting a funnel plot [26]; publication bias is unlikely if
the funnel plots shows a symmetrical inverted V shape [27]. All
analyses were performed using the open source statistical package,
R 2.9.0 (R Foundation for Statistical Computing).
Results
Identification and Description of Included Studies
Figure 1 outlines identification of studies for this systematic
review. The literature search identified 73 potentially relevant
studies, of which only 30 fulfilled the inclusion and quality criteria
(details of excluded studies can be found in Text S2) [28–57]. We
obtained further data from three studies after contacting authors
(Figure 1), giving a total of 33 studies to be included in the
systematic review [58–60].
The 33 studies reported data obtained from 14 separate
prospective cohort studies and six separate treatment-to-reinfec-
tion population studies (Tables 1 and 2, respectively) indicating
that multiple publications arise from a single population-based
study. For the purpose of this review we shall refer to each
publication as a study. The majority of studies report data from
Africa (28/33; 84.8%), with three in Papua New Guinea, one in
Asia, and one from South America. Study size ranged from 80 to
1,071 participants (median=280) and duration of participant
follow-up ranged from 3 to 18 mo (median=6). The association of
antibody responses to MSP-1 (including processing fragments and
defined blocks), MSP-2, and MSP-3, AMA-1, EBA-175, and
GLURP with incidence risk of P. falciparum malaria was examined
in 19, eight, seven, five, three, and six studies, respectively. Details
of recombinant proteins and sero-prevalences can be found in
Text S2 (Tables A and B). All studies measured total IgG by
ELISA with the exception of Gray et al. (2007), who measured
IgG by microarray [40]. Symptomatic P. falciparum malaria during
follow-up was the most common outcome, examined in 29 studies;
with reinfection and high density infection during follow-up
examined in five and three studies, respectively. No study
examined the association of anti-merozoite responses with
incidence risk of severe P. falciparum malaria or P. falciparum
malaria-associated mortality.
Association between Anti-MSP-1 Responses and
Incidence of P. falciparum Malaria
MSP-1 C-terminal (Ct)–processing fragments. MSP-1 is
a high molecular mass protein (Mr<180 kDa) that is
proteolytically processed into 83 kDa, 30 kDa, 38 kDa, and C-
terminal 42 kDa (MSP-142) fragments [61]. During invasion,
MSP-142 is further processed into MSP-119 and MSP-133
fragments. Both MSP-119 and MSP-142 are regarded as
potential vaccine candidates and have been shown to be
protective in animal models [17]. Meta-analysis of five studies
showed that MSP-119 IgG responders had an 18% reduction in
the risk of symptomatic P. falciparum malaria compared to
nonresponders (pooled RR using random-effects [reRR] 0.82,
95% CI 0.7–0.96, p=0.012; Figure 2) [31,36,43,50,59]. Meta-
regression analysis revealed heterogeneity between allelic groups
(p=0.0223) with the greatest magnitude of effect seen with
MAD20 and Palo Alto alleles (29% and 33% relative reduction in
symptomatic disease, respectively; Figure 2). Because the methods
for the preparation of each antigen was the same for each allelic
variant (Text S2, Table A) similar results were obtained when
grouping according to expression system and tag used to make the
recombinant antigen. Other methodological and clinical
characteristics of the studies did not influence estimates and
there was no evidence of publication bias.
Data were obtained from a further three studies and pooled to
examine the dose-response association of MSP-119 levels (log base
2) and the risk of malaria [29,44,55]. A 15% reduction in
symptomatic P. falciparum per doubling of antibody levels was
observed (reRR 0.85, 95% CI 0.74–0.97, p=0.019; Figure 2).
With only three studies in the meta-analysis, further subgroup
analysis was not feasible. One additional study examined the
association of antibody levels (excluded from meta-analysis
because transformation, if any, was not stated in the original
manuscript) with symptomatic P. falciparum and found weak
evidence of a protective effect (RR 0.97, 95% CI 0.94–1.00,
p=0.0713) [56]. There was no conclusive evidence to support an
association between anti-MSP-119 responses with P. falciparum high
density infection or reinfection (see Text S2).
MSP-119 is made up of two epidermal growth factor-like
modules (EGF-1 and EGF-2). Meta-analyses showed no associa-
tion between the presence of responses to either MSP-1-EGF1 or
MSP-1-EGF2 with protection against symptomatic P. falciparum
(RR 1.06, 95% CI 0.88–1.26, p=0.56 and reRR 0.59, 95% CI
0.19–1.84, p=0.37; I
2=71.4%, 95% CI 2.8–91.6%, respectively)
[36,41]. For individual study estimates see Text S2.
Only one study examined the association of MSP-142 levels (log
base 2) with incidence risk of symptomatic P. falciparum and found
a reduced risk (RR 0.76, 95% CI data not shown in original
manuscript [DNS], p#0.001) [49].
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can be grouped into three allelic types, K1-like, RO33-like, and
MAD20 like. The association of incidence risk of symptomatic P.
falciparum with allelic specific MSP-1 block 2 responders compared to
nonresponders was examined in four studies [31,40,43,59]. Pooled
results were done separately for each allelic type. Meta-analysis
revealed no evidence of an association with the K1-like (reRR 0.88,
95% CI 0.67, 1.17, p=0.39) or RO33-like allele (RR 0.99, 95% CI
0.81, 1.21,p=0.91) (Figure 3). There wasweak evidence ofa protective
effect of MAD20-like responses with incidence risk of symptomatic P.
falciparum (reRR 0.79, 95% CI 0.6, 1.04, p=0.093; Figure 3).
The K1-like and MAD20-like types of MSP-1 block 2 differ in the
length of tri-peptide repeats in the middle of the block as well as the
flanking nonrepetitive sequences. Meta-analysis was performed on
threestudiesinvestigatingtheassociationbetweenresponsestoMSP-
1 block 2 repeats and flanking regions (responders versus
nonresponders) and incidence risk of symptomatic P. falciparum
[32,40,43]. There was some evidence of an association for MSP-1
block 2 K1-like repeats (RR 0.72, 95% CI 0.54–0.97, p=0.031)but
not MSP-1 block 2 MAD20-like repeats (reRR 0.79, 95% CI 0.48–
1.3, p=0.35) (Figure 4).Therewasalsono evidence ofanassociation
between MSP-1 block 2 flanking regions with risk of symptomatic P.
falciparum (K1-like RR 0.87, 95% CI 0.66–1.14, p=0.31 and
MAD20-like reRR 0.84, 95% CI 0.52–1.34, p=0.46; Figure 4).
Combined results from two studies showed no evidence of an
association of MSP-1 block 1 responses with risk of symptomatic
falciparum malaria (responders versus nonresponders RR 0.96,
95% CI 0.57–1.62, p=0.88; Figure 4) [31,43].
Figure 1. Flow chart of study identification. Details of excluded studies can be found in Text S2.
aDefinition of symptomatic malaria did not meet
protocol definition;
bAnalysed retro- and prospectively collected clinical data (n=3), analysed antibody levels as outcome (n=4,) and data presented on
P. falciparum positive individuals only (n=1);
cReasons for exclusion: Data from seroprevalence surveys (n=15); hospital-based study/recruited cases
based on clinical/parasitemic status (n=6); did not include malaria outcome of interest (n=5); mother/infant studies (n=3); measured IgG responses to
undefinedregions of antigens(n=1);
dScopeletal.(2007) provideddata usinga definitionofsymptomaticmalaria that met ourquality criteria,Sarr etal.
(2006) provided data so P. falciparum could be analysed as outcome, and Osier et al. (2008) provided estimates for the whole cohort, whereas the
manuscript originally presented data from P. falciparum-positive individuals only [58–60];
eThe characteristics of included studies are given in Table 1.
doi:10.1371/journal.pmed.1000218.g001
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The single msp2 locus of P. falciparum is highly polymorphic but
can be grouped into two major allelic types, 3D7 and FC27. Meta-
analysis of six studies investigating MSP-23D7 and MSP-2FC27
showed no evidence of a reduced risk of symptomatic P. falciparum
in those with responses compared to those without responses
(MSP-23D7, reRR 0.92, 95% CI 0.75–1.13, p=0.43;
Table 1. Characteristics of prospective studies included in the systematic review by country.
Country
Study: Author,
Year [Reference] Province
Follow-
up (mo) Population Merozoite IgG Response P. falciparum Outcome
Sample
Size
Age
(y) Source
Incidence Outcome
(Cumulative Incidence %)
Brazil Scopel, 2007 [58] Acre 15 356 5–65 MSP-2 ACD, PCD Symptomatic Pf
c (6.5)
Burkina Faso Meraldi, 2004 [28] Kadiogo 7 293 0.5–9 GLURP, MSP-3 ACD Symptomatic Pf
d (49)
Nebie, 2008 [29] Bazega 4 286 0.5–15 AMA-1, GLURP, MSP-119, MSP-3 ACD Symptomatic Pf
d (41)
Nebie, 2008 [30] Bazega 4 360 0.5–10 GLURP, MSP-3 ACD Symptomatic Pf
d (DNS)
The Gambia Conway, 2000 [31]
a Upper River 5 337 3–7 MSP-119, MSP-1-BL1, MSP-1-BL2 ACD, PCD Symptomatic Pf
d (19)
Polley, 2003 [32]
a Upper River 5 334 3–7 MSP-1-BL2 ACD, PCD Symptomatic Pf
d (19)
Metzger, 2003 [33]
a Upper River 5 329 3–7 MSP-2 ACD, PCD Symptomatic Pf
d (19)
Polley, 2007 [34]
a Upper River 5 319 3–7 MSP-3 ACD, PCD Symptomatic Pf
d (19)
Dziegiel, 1993 [35]
a North Bank 6 385 3–8 GLURP ACD Symptomatic Pf
d (35)
Egan, 1996 [36]
a North Bank 6 327 3–8 MSP-119, MSP-1-EGF ACD Symptomatic Pf
d (35)
Taylor, 1998 [37]
a North Bank 6 355 3–8 MSP-2 ACD Symptomatic Pf
d (35)
Okenu, 2000 [38]
a North Bank 6 284 3–8 EBA-175 ACD Symptomatic Pf
d (35)
Okech, 2004 [39]
a North Bank 6 260 3–8 MSP-119
b ACD Symptomatic Pf
d (35)
Gray, 2007 [40]
a North Bank 6 189 3–8 AMA-1, MSP-119,
b MSP-1-BL2,
MSP-2,
b MSP-3
ACD Symptomatic Pf
d (35)
Ghana Dodoo, 1999 [41]
a Greater
Accra
18 266 3–15 MSP-119,
b MSP-1-EGF ACD, PCD Symptomatic Pf
e (41)
Dodoo, 2000 [42]
a Greater
Accra
18 115 3–15 GLURP ACD, PCD Symptomatic Pf
e (41)
Cavanagh, 2004 [43]
a Greater
Accra
18 280 3–15 MSP-119, MSP-1-BL1, MSP-1-BL2 ACD, PCD Symptomatic Pf
e (41)
Dodoo, 2008 [44] Greater
Accra
9 352 3–10 AMA-1, GLURP, MSP-119, MSP-3 ACD, PCD Symptomatic Pf
e (19)
Kenya Polley, 2004 [45]
a Coast 6 1,071 0.1–85 AMA-1 ACD, PCD Symptomatic Pf
f (15, 26)
Polley, 2006 [46]
a Coast 6 1,068 0.1–85 MSP-2 ACD, PCD Symptomatic Pf
f (15, 26)
Osier, 2007 [47]
a Coast 6 536 0.1–85 MSP-3 ACD, PCD Symptomatic Pf
f (15)
Osier, 2008 [59]
a Coast 6 280 0.1–85 EBA-175, MSP-119, MSP-1-BL2 ACD, PCD Symptomatic Pf
f (24)
Papua New
Guinea
Al-Yaman, 1995 [48]
a East Sepik 12 230 0.5–15 MSP-2 ACD, PCD Symptomatic Pf
e (DNS)
Al-Yaman, 1996 [49]
a East Sepik 12 230 0.5–15 MSP-142 ACD, PCD Symptomatic Pf
e (DNS)
Senegal Perraut, 2005 [50] Fatick 5 205 3–75 MSP-119 ACD, PCD Symptomatic Pf
g (60)
Sarr, 2006 [60] Fatick 6 169 2–10 MSP-2 ACD Symptomatic Pf
h (53)
Sierra-Leone Egan, 1996 [36] Southern 12 645 0–8 MSP-119, MSP-1-EGF ACD Symptomatic Pf
d (42)
Tanzania Lusingu, 2005 [51] Tanga 6 171 0–19 GLURP ACD, PCD Symptomatic Pf
e (32)
Sample size refers to number of participants whose serology was determined. IgG responses measured by ELISA with the exception of Gray et al. [40] who used
microarray immunoassays. Manuscripts by Egan et al. [36] and Okech et al. [39] report studies performed in two countries and feature twice in Table 1 and once in
Tables 1 and 2, respectively. Studies by Polley et al. [45,46] in the Kenyan coast were done at two study sites.
aIndicates that the different antibody association studies were performed in the same cohort for the specified country and province. In The Gambia, the ‘‘Upper River’’
and ‘‘North Bank’’ studies were separate cohorts.
bAntigen was not included in meta-analysis (as per protocol).
Malaria definitions:
cHistory of fever plus P. falciparum .300/ml.
dFever plus P. falciparum $5,000/ml or fever plus P. falciparum .5,000/ml.
eFever or history of fever (within the past 72 h) plus P. falciparum $5,000/ml.
fFever plus an age-dependent threshold of P. falciparum.
gFever plus .30 P. falciparum trophozoites/100 leukocytes.
hFever plus P. falciparum .2,500/ml.
Pf, P. falciparum.
doi:10.1371/journal.pmed.1000218.t001
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[33,37,46,55,58,60]. Methodological and clinical characteristics of
the studies did not influence estimates and there was no evidence
of publication bias. One additional study found a dose-dependent
response with MSP-23D7 antibody levels (log base 2) and risk of
symptomatic P. falciparum (RR 0.81, 95% CI DNS, p=0.003) but
not MSP-2FC27 (RR 0.99, 95% CI DNS, p=0.86) [48]. Another
study examined the effect of MSP-2-Ct (responders versus
nonresponders) and found no evidence of an association with
symptomatic P. falciparum (RR 0.55, 95% CI 0.27, 1.14, p=0.11)
[33]. Only one study examined the association of MSP-2
antibodies with reinfection and high density infection and found
no association (see Text S2) [55].
Association between Anti-MSP-3 Responses and
Incidence of P. falciparum Malaria
The C-terminal region of MSP-3 (MSP-3-Ct) is highly
conserved whereas the remainder of the sequence is defined by
two major allelic types, 3D7 and K1 [62]. Meta-analyses of four
studies [28,30,34,47] examining antibodies to MSP-3-Ct responses
showed a 54% reduction in symptomatic P. falciparum in
responders versus nonresponders (RR 0.46, 95% CI 0.32–0.67,
p,0.0001; Figure 6). Meta-analyses of two studies also showed a
decreased incidence risk per doubling of MSP-3-Ct antibody levels
(RR 0.73, 95% CI 0.6–0.88, p=0.001, Figure 6) [29,44].
Three studies examined the association of full length MSP-33D7
and MSP-3K1 responses (responders versus nonresponders) with
risk of symptomatic P. falciparum [34,40,47]. Meta-analysis showed
no evidence of an association with anti-MSP-33D7 responses (reRR
0.92, 95% CI 0.64–1.31, p=0.63; Figure 6), but a large amount of
heterogeneity was observed (I
2=67.6%, 95% CI 0–90.6%). A
high degree of heterogeneity was also seen for MSP-3K1
associations (I
2=76.8%, 95% CI 24.4–92.9) so results were not
combined (Figure 6). Due to the small number of studies in these
meta-analyses, exploration of heterogeneity by subgroup analysis
was not feasible.
Association between anti-AMA-1 Responses and
Incidence of P. falciparum Malaria
There are currently two different AMA-1 strains of the full-
length ectodomain under development as vaccine candidates
(FVO and 3D7) [17]. There was evidence of reduced risk of
symptomatic P. falciparum with AMA-13D7 responders versus
nonresponders (RR 0.79, 95% CI 0.65–0.96, p=0.015), and
there was also a tendency towards a protective effect in the study
that examined tertiles (Figure 7) [40,45,55]. For AMA-1FVO, one
study showed a reduced risk of symptomatic P. falciparum in AMA-
1FVO responders compared to nonresponders (RR 0.66 95% CI
0.52–0.84, p=0.0007), but combined results of two studies showed
no association of anti-AMA-1FVO levels (log base 2) with incidence
risk of symptomatic P. falciparum (RR 0.99, 95% CI 0.9–1.08,
p=0.76; Figure 7) [29,44,45]. There was insufficient evidence to
show an association between AMA-1 responses with risk of
reinfection and high density P. falciparum (see Text S2).
Association between Anti-GLURP Responses and
Incidence of P. falciparum Malaria
GLURP can be divided into an N-terminal nonrepeat region
(R0), a central repeat region (R1), and a C-terminal repeat region
(R2). A reduced risk of symptomatic P. falciparum was shown in
GLURP-R0 responders compared to nonresponders (RR 0.69,
95% CI 0.48–0.97, p=0.032) and per doubling of antibody levels
(RR 0.79, 95% CI 0.69–0.91, p=0.0006; Figure 8) [29,30,44].
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PLoS Medicine | www.plosmedicine.org 7 January 2010 | Volume 7 | Issue 1 | e1000218Dodoo et al. (2000) also reported that anti-GLURP-R0 levels were
associated with protection (p,0.005), but no estimates or 95% CI
were given [42]. Conversely, Lusingu et al. (2005) reported no
association with anti-GLURP-R0 responders with odds (RR were
incalculable) of symptomatic episode (OR 1.13, 95% CI 0.5–2.53,
p=0.77) [51].
GLURP-R2 was associated with protection to varying degrees.
Meraldi et al. and Nebie et al. showed a 90% (RR 0.1, 95% CI
0.05–0.23, p,0.001) and 27% (RR 0.73, 95% CI 0.5–1.06,
p=0.1; Figure 8) reduction in symptomatic malaria in responders
versus nonresponders [28,30]. Estimates from these two studies
were not combined (I
2=94.5%). Another study found no evidence
of an association between anti-GLURP-R2 (p=0.2) or GLURP-
R1 (p=0.3) levels (estimates and 95% CI, DNS) [42]. One study
examined the association of GLURP-R1-R2 with malaria, which
showed a reduced risk of symptomatic P. falciparum (RR 0.73, 95%
CI 0.55–0.97, p=0.03) [35].
Association between Other Responses and Incidence of
P. falciparum Malaria
Only three studies meeting our inclusion and quality criteria
measured anti-EBA-175 responses [38,53,59]. Osier et al. (2008)
(used recombinant F2 domain) and Okenu et al. (2000) (used
recombinant region II) showed no association of anti-EBA-175
antibodies with risk of symptomatic P. falciparum (responders versus
nonresponders, RR 1.36, 95% CI 0.81–2.3, p=0.246 for Osier
et al.; RR 0.96, 95% CI 0.71–1.29, p=0.77 for Okenu et al.). John
et al. (2005) showed no association between antibodies (to region
Figure2.ForestplotoftheassociationofMSP-119responseswithincidenceofsymptomaticP.falciparummalaria.RRscorrespondtoriskof
symptomaticP.falciparummalariaforMSP-119respondersversusnonresponders andper doublingofantibodyresponses(logbase2).RR,1 indicatethat
antibodyresponsesareprotectiveagainstsymptomaticP.falciparumwhereasRR.1indicatesusceptibility.
aEstimatesarecalculatedbyauthorsfromdata
in the paper;
bdata supplied by original authors and calculated by current authors;
cestimates are published estimates. All estimates are unadjusted with
the exceptionofestimates from Nebieetal. (2008)and Dodoo etal. (2008), which are adjusted for age, andestimates fromStanisic (2009)are adjustedfor
age and spatial confounders [29,44,55]. W, weight. Note: Egan, 1996 had two study sites *Sierra-Leone and **The Gambia, and their analysis only included
those with clinical disease versus asymptomatics, i.e., excluded those uninfected as they were assumed to be unexposed [36].
doi:10.1371/journal.pmed.1000218.g002
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PLoS Medicine | www.plosmedicine.org 8 January 2010 | Volume 7 | Issue 1 | e1000218Figure 3. Forest plot of the association of MSP-1 block 2 and block 1 responses with incidence of symptomatic P. falciparum malaria.
RRs represent the risk of symptomatic P. falciparum malaria in IgG responders relative to nonresponders. RR,1 indicate that responders are protected
from symptomatic P. falciparum whereas RR.1 indicate susceptibility.
aEstimates are published estimates;
bestimates are calculated by authors from
data in the paper;
cdata supplied by original authors and calculated by current authors. All reported estimates are unadjusted. W, weight.
doi:10.1371/journal.pmed.1000218.g003
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PLoS Medicine | www.plosmedicine.org 9 January 2010 | Volume 7 | Issue 1 | e1000218Figure 4. Forest plot of the association of MSP-1-block 2 repeats and flanking region responses with incidence of symptomatic P.
falciparum malaria. RRs represent the risk of symptomatic P. falciparum malaria in IgG responders relative to nonresponders. RR,1 indicate that
responders are protected from symptomatic P. falciparum whereas RR.1 indicate susceptibility.
aEstimates are published estimates;
bestimates are
calculated by authors from data in the paper. All reported estimates are unadjusted. W, weight.
doi:10.1371/journal.pmed.1000218.g004
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PLoS Medicine | www.plosmedicine.org 10 January 2010 | Volume 7 | Issue 1 | e1000218II) and risk of reinfection (.75 percentile versus ,75% percentile
1.25, 95% CI 0.66–2.36, p=0.49). One study investigated the
relationship between MSP-4 and MSP-4-EGF1 with risk of
reinfection and showed no association (RR 0.9, 95% CI 0.58–
1.39, p=0.64 and RR 0.8, 95% CI 0.56–1.15, p=0.22,
respectively) [57].
Discussion
This systematic review strongly supports the protective effect of
total IgG responses to particular merozoite surface antigens
against symptomatic P. falciparum malaria in humans. Meta-
analyses showed that individuals who have IgG to MSP-3-Ct and
MSP-119 have a risk of symptomatic P. falciparum that is 54% and
18%, respectively, less than those without detectable IgG.
Moreover, there was evidence of a dose-response relationship
such that the magnitude of association with these antigens
increased per doubling of antibody levels. A tendency towards
protective RR was also observed when individual estimates for
AMA-13D7 and GLURP-R0 were examined, but pooled estimates
of more than two studies could not be determined owing to
heterogeneity among studies. Pooled estimates showed limited
evidence of a protective effect of IgG responses towards MSP-2,
MSP-1 N-terminal region, or MSP-1-EGF subregion with
Figure 5. Forest plot of the association of MSP-2 responses with incidence of symptomatic P. falciparum malaria. RR,1 indicate that
responders are protected from symptomatic P. falciparum compared to nonresponders whereas RR.1 indicate susceptibility.
aEstimates are
published estimates;
bconverted published estimate;
cestimates are calculated by authors from data supplied by original author;
destimates are
calculated by authors from data in the paper. W, weight. Estimates reported are unadjusted with the exception of Stanisic (2009) (adjusted for spatial
confounders and age) and Metzger (2003) (adjusted for age and preseason parasitaemia) [33,55]. Note that estimates for Taylor (1998) are based on
clinical and asymptomatic cases only (i.e., those uninfected were excluded on the basis they were unexposed) [37]. Polley (2006) stratified for two
study sites in Coastal Kenya, *Chonyi and **Ngerenya [46].
doi:10.1371/journal.pmed.1000218.g005
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PLoS Medicine | www.plosmedicine.org 11 January 2010 | Volume 7 | Issue 1 | e1000218Figure 6. Forest plot of the association of MSP-3 responses with incidence of symptomatic P. falciparum malaria. RR,1 indicate
protection from symptomatic P. falciparum whereas RR.1 indicate susceptibility in responders versus nonresponders or per doubling of antibody
responses. Estimates reported are unadjusted with the exception of Nebie (2008) (adjusted for age, sex, and village) [30] and Nebie (2008) and Dodoo
(2008) (adjusted for age) [29,44].
aEstimates are calculated by authors from data in the paper;
bestimates are published estimates. All reported
estimates are unadjusted. W, weight.
doi:10.1371/journal.pmed.1000218.g006
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PLoS Medicine | www.plosmedicine.org 12 January 2010 | Volume 7 | Issue 1 | e1000218symptomatic P. falciparum malaria. Importantly, this systematic
review revealed a paucity of studies examining the association of
IgG responses towards the vaccine candidates MSP-142 and EBA-
175 with incidence of P. falciparum malaria.
Heterogeneity, in terms of both clinical and methodological
diversity between studies, was an important issue in the meta-
analyses. Clinical heterogeneity was noted in MSP-119 meta-
analyses whereby the magnitude of effect varied with allelic group.
Figure 7. Forest plot of the association of AMA-1 responses with incidence of symptomatic P. falciparum malaria. RRs correspond to risk of
symptomatic P. falciparum malaria for AMA1 responders versus nonresponders, High (H) and medium (M) versus low (L) responders (based on tertiles because
sero-prevalence was high) and per doubling of antibody responses (log base 2). RR,1 indicate that antibody responses are protective against symptomatic P.
falciparum whereas RR.1 indicate susceptibility.
aEstimates are calculated by authors from data in the paper;
bestimates are published estimates;
cestimates
supplied by the original authors. All estimates are unadjusted with the exception of Dodoo (2008) and Nebie (2008) with adjustments for age and Stanisic
(2009) with adjustments for age and spatial confounders [29,44,55]. Polley (2004) stratified for two study sites in Coastal Kenya, *Chonyi and **Ngerenya.
doi:10.1371/journal.pmed.1000218.g007
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PLoS Medicine | www.plosmedicine.org 13 January 2010 | Volume 7 | Issue 1 | e1000218However, given that MSP-119 is relatively conserved and that the
different alleles are based on four amino acid changes, the
biological relevance of this observation is unknown. Methodolog-
ical heterogeneity was most evident across studies investigating
AMA-1 and GLURP responses. Antibody variables were defined
differently across studies and estimates with errors and/or raw
data were not presented. Subsequently the standardization of
antibody variables and pooling of results was problematic.
Statistical heterogeneity (I
2 value) was greatest for GLURP R2
and the full length MSP-3 antigen meta-analyses.
There are many factors influencing the selection of antigens for
vaccine development and testing in clinical trials, and evidence
from observational studies can provide valuable knowledge to
inform this process. MSP-119 was the most featured merozoite
surface antigen and meta-analyses showed that antibody responses
to MSP-119 were indicative of protection. It is thus surprising that
MSP-119 has only featured in one vaccine in humans, in which it
was used in combination with AMA-1 (PfCP2.9/ISA720) in phase
I trials [63,64]. Conversely, only one study has demonstrated
evidence of protection for antibodies to MSP-142, but this antigen
has been tested in a phase II vaccine trial where it was not
protective [65]. The reasons for the failure of this vaccine remain
unclear, but may relate to antigen polymorphism or the nature of
the vaccine-induced response, or instead may indicate that MSP-
142 antibodies are not protective. Further studies of this antigen
are clearly needed. Other merozoite surface antigens currently
undergoing phase II trials in malaria endemic countries include
AMA-1 (AMA-C1, which includes 3D7 and FVO strains) and
MSP-3 (as a long synthetic peptide and a MSP-3/GLURP
chimera), which were shown to be protective against symptomatic
malaria in this review [17]. There are currently no vaccines with
MSP-1-block 1 and 2 proteins, and data from this systematic
review does not support the development of these antigens as
vaccine targets.
The aim of this systematic review was to be as comprehensive
and inclusive as possible and fulfil guidelines for meta-analyses
[19]. We performed an extensive search of six different databases
and did not limit our searches by language to remove the potential
for bias due to exclusion of non-English studies [66]. Furthermore,
we identified and contacted the investigators for the studies that
did not meet our initial inclusion and quality criteria but contained
potential data. In addition, instead of excluding studies that did
not provide estimates, we contacted authors and asked them to
provide estimates or data. We did not limit our review to IgG
subclasses as it would substantially decrease the number of studies
included. Examining subclass-specific responses to merozoite
antigens has provided further insights into protective targets and
mechanisms of acquired immunity [55,67]. However, differences
in the specificity and sensitivity of subclass-typing reagents
between studies makes comparisons between studies difficult. We
also assessed publication bias where possible, although in some
cases where only a few studies were combined this assessment was
difficult. The extent to which the selective publication of studies
based on the direction and magnitude of findings within malaria
Figure 8. Forest plot of the association of GLURP responses with incidence of symptomatic P. falciparum malaria. RRs correspond to
risk of symptomatic P. falciparum malaria for GLURP responders versus nonresponders and per doubling of antibody responses (log base 2). RR,1
indicate that antibody responses are protective against symptomatic P. falciparum whereas RR.1 indicate susceptibility.
aEstimates are published
estimates with adjustments for age, Nebie (2008) responder versus nonresponder analysis also adjusted for sex and village [30];
bestimates are
calculated by authors from data in the paper. GLURP-R2 estimates were not combined because I
2.75%. W, weight.
doi:10.1371/journal.pmed.1000218.g008
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studies regardless of findings should be encouraged.
Determining a causal relationship between antibodies and
protection against P. falciparum malaria is one of the main
challenges in malaria immuno-epidemiology. Study designs used
in the published literature include cross-sectional studies, case-
control studies, and cohort studies. To ensure the best inference of
causality from the published literature we did two things. Firstly,
we only included studies that examined the association of
antibodies with prospectively collected P. falciparum data to
establish a temporal relationship between antibody responses
and risk of P. falciparum malaria. Secondly, we included a
parasitaemia density cut-off in our definition of symptomatic
malaria as part of our quality criteria to improve specificity and
ensure that P. falciparum was the causative agent of the febrile
episode. The prevailing view in the field is that a cut-off level of
parasitaemia is needed to improve the specificity of clinical malaria
diagnosis in most populations [68–70]. The population-specific
definitions of a high P. falciparum density cut-off in the studies
ranged from .300 parasites/mlt o.5,000 parasites/ml and the
sensitivity of these definitions would vary across populations. In
addition, we would expect reduced specificity of the definition for
the one study that reanalysed data with a high density cut-off for
inclusion in our review [58].
A causal relationship between anti-merozoite antibodies and P.
falciparum malaria is strengthened by the consistent demonstration
of findings under different circumstances. Consistent findings were
demonstrated for some antigens despite differences in the
preparation of antigens, malaria endemicity, study participants,
and study area. Interestingly, we found very few published studies
that were performed outside Africa. Of the 32 included studies,
only one was performed in Asia (excluding Papua New Guinea)
and only one in South America (see Table 1). The generalizability
of our findings to populations living in these less-represented
regions is unknown. Additionally, we only identified two studies
that investigated allele-specific immunity (both studies MSP-2
only), whereby the allele-specific antibody response was related to
the strain causing the malaria episode [55,58]. If protection is
purely allele-specific then the true causal protective effect will be
underestimated in studies that do not use allele-specific P.
falciparum outcomes.
Another important limitation in published literature is that
data generated by ELISA does not produce a common metric
measurement thereby restricting the standardization of expo-
sure variables. In meta-analyses we were able to pool RR for
responders versus nonresponders and RR derived from log base
2 antibody levels, which represent the change in risk per
doubling of antibody levels. However, antibody concentrations
vary across populations according to the level of exposure to
malaria. Therefore the magnitude of effect according to
quantified responses may vary significantly across studies. This
was evident by the dose-dependent relationships between some
antibody responses and level of protection and would suggest
that antibody responses need to be quantified. Furthermore,
knowledge on how long specific merozoite antibody responses
last, how they are boosted, and the duration of any protection
from responses is presently limited. The duration of the follow
up in observational studies may therefore have an impact on the
strength and direction of an association, an effect we explored in
meta-regression. Further studies that measure responses at
multiple time points are needed to better understand these
issues.
The definition of ‘‘protected’’ individuals (i.e., those who did not
have symptomatic malaria) varied across studies. For most studies
this definition included all participants who had no recorded
episodes of symptomatic P. falciparum malaria. Three studies
excluded individuals who did not have any detected parasitaemia
during follow-up from the ‘‘protected’’ group, on the basis that
these individuals were unexposed [35–37]. Only the six treatment-
to-reinfection studies had regular blood collection for detection of
parasitaemia; all other included studies only collected blood slides
during follow-up when an individual was febrile, so accurately
determining true ‘‘unexposed’’ individuals in areas where
asymptomatic parasitaemia is prevalent will be problematic.
Recent analyses by Bejon et al. (2009) of anti-VSA antibodies in
individuals living in Kilifi, Kenya, showed that by removing
unexposed children from conventional analyses, the magnitude of
effect was greater between those with high and low responses [71].
This is consistent with other studies in Kilifi that showed that
associations between specific merozoite antibody responses and
protection were stronger in children who were asymptomatic at
baseline [45,46,59]. A further consideration is that studies in
malaria-endemic areas typically compare individuals with different
levels of immunity, not individuals with complete immunity versus
individuals with no immunity. Therefore, the reported effect size
may not accurately reflect the true magnitude of the response in
the study population.
Conclusion and Guidelines for Future Research
IgG responses to some, but not all, merozoite surface antigens
were associated with protection against symptomatic P. falciparum
in malaria endemic areas. We identified very few antigens that had
been well studied and a deficiency of studies done outside Africa.
More studies in different populations, examining multiple antigens
at multiple time-points, are needed to better determine the role of
anti-merozoite antibodies in protection against malaria, with
prospective cohort studies as the preferred study design to establish
temporal causality. In the future, there should be as much
uniformity between studies as possible to ensure maximum
comparability. This could be improved by the quantification and
standardization of IgG responses, which could be achieved by
establishing a reference reagent for determining antibody
concentrations. Furthermore, the protective effects of anti-
merozoite responses observed epidemiologically must also be
supported by evidence of the function of the antibodies.
Development and application of functional assays rather than
standard immunoassays would also be highly valuable. Presently,
data on the function of antibodies against merozoite antigens is
very limited [8,12,15,72]. Lastly, there is a need to incorporate
strain-specific responses and endpoints to address whether
protective responses against particular antigens are strain-tran-
scending or strain-specific.
A challenging aspect of this systematic review was the
standardization of exposure and outcome measurements as there
is no consistent approach to reporting of data. To facilitate the
standardization of results in future studies, we propose guidelines
for the reporting of malaria immuno-epidemiology studies adapted
from the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement (Table 3) [73,74]. Standard-
izing studies, and removing as much methodological heterogeneity
as possible, will help obtain more comparable results in the future.
By doing so, we will then be in a more favourable position to assess
the relative contribution of responses to certain antigens, thereby
informing vaccine candidate choices.
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Meta-analysis of Immunity to Malaria
PLoS Medicine | www.plosmedicine.org 15 January 2010 | Volume 7 | Issue 1 | e1000218Table 3. Proposed guidelines of the reporting of Malaria Immuno-epidemiology Observational Studies (MIOS guidelines).
Report Section Topics Recommended Inclusions
Title and abstract — Indicate the study design and the study population
— Provide in the abstract an informative and balanced summary of what was done and the main
findings. Indicate immune response measured, antigens used, and all Plasmodium and clinical end-
points examined. Present key estimates of associations with measures of variability.
Introduction — Explain the scientific background and rationale for the antigens and Plasmodium end-points chosen.
— State objectives, including any prespecified hypotheses (i.e., protection, no effect).
— State how the current study will add to the malaria immuno-epidemiology literature and briefly state
how it compares to previous studies.
Methods Epidemiological study A description of the setting, including location, Plasmodium spp. found in the area, rate of malaria
transmission, dates of transmission. Mention any recent changes in endemicity.
— Study design, describe exactly how and when immune response, Plasmodium and clinical data
collection took place. For longitudinal studies discriminate between serial cross-sectional studies and
longitudinal cohort studies.
— Relevant dates such as participant recruitment, measurement of immune responses, follow-up, and
Plasmodium and clinical data collection.
— Eligibility criteria and sources and methods of selection of participants. Justification of criteria.
Methods of follow-up and data collection. Indicate intervals for ACD and the appropriateness of the
use of PCD in the setting. Indicate how presumptive malaria diagnosis was dealt with in data
collection.
— A description of any efforts to address potential sources of bias.
— Sample size calculations. Include the level of precision and power, the expected size of differences to
be measured (e.g., in antibody levels, risk/odds of malaria), and the minimum difference you wish to
detect.
Variables Definitions of all Plasmodium outcomes (i.e., parasitaemia, symptomatic malaria), detail
parasitological cut-offs and fever definitions. State whether Plasmodium speciation was done and
how this was incorporated into definitions. Mention the sensitivity and specificity of malaria
definitions in the population. Indicate how ‘‘unexposed’’ individuals were defined, if relevant.
— Definitions of all immunological variables. Explain how responders and nonresponders were defined.
Explain how continuous variables were handled in the analyses such as the use of transformations
and groupings. Describe which groupings were chosen and why, and state the cut-offs used for each
group and the category mean or median values. For each antigen indicate the allele, amino acid
position, expression system, and tag. Provide gene accession numbers.
— A list of all potential confounders and effect modifiers that were considered with justification. These
should at least include age, Plasmodium status at baseline, and variables that represent level of
transmission/exposure (e.g., spatial confounders).
Statistical analysis Rationale for statistical approach considering study design and distribution of immunological and
Plasmodium data. Make particular note of any collinearity issues with immunological data.
— Description of all statistical methods, including those used to control for confounding, examine
subgroups and interactions (particularly with age) and any sensitivity analyses. Explain how missing
data were addressed if relevant.
— Details and justification of all data transformations explored during analysis. State any assumptions
of linearity in immunological data. State whether categories generated from continuous antibody
variables were used as a nominal or ordinal variable (i.e., classified into unordered or ordered
qualitative categories).
Results Study participants The numbers of individuals at each stage of the study and any groups excluded from analysis.
— The demographic and clinical characteristics of the participants and information on exposures and
potential confounders. Indicate the number of participants with missing data for each variable of
interest. Summarize follow-up times if applicable and mention changes in incidence of Plasmodium
over follow-up. Consider presenting clinical and immunology data according to age group to give
the reader a sense of the acquisition of immunity in the study population or by immunological
response categories so they can be related to confounders.
Immunological responses and
malaria measures
Mean (standard deviation) or median (percentiles/range) of values to describe measures of central
tendency and the spread of data measured in the study. Do not use inferential measures such as
standard errors or confidence intervals.
— Details of any quantification of antibody or other concentrations (i.e., titres in mg/ml).
— Counts of cases, controls, person-time at risk, risk etc. for each immune response category in
addition to effect-measure estimates and results of model fitting.
Risk estimates Unadjusted and adjusted estimates of risk and their precision, e.g., 95% CIs. This will allow the reader
to judge by how much, and in what direction, they changed. Make clear which confounders were
adjusted for and why they were included. Provide risk estimates for all immunology variables
investigated (i.e., responders versus nonresponders and any dose-dependent variables).
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Background. Plasmodium falciparum malaria, a mosquito-
borne parasitic infection, kills about one million people every
year. Around a week after an infected mosquito has bitten a
person, ‘‘merozoites’’ (one of the life-stages of the parasite)
infect the person’s red blood cells where they replicate and
then burst out and infect more red blood cells. Rapid
replication of parasites can occur in the bloodstream, leading
to massive numbers of parasites that can damage vital
organs. Although individuals can lower their risk of
becoming infected with malaria parasites by avoiding
mosquito bites, a vaccine is urgently needed to reduce the
global burden of malaria. When malaria parasites infect a
person for the first time, the human immune system begins
to produce antibodies, proteins that recognize molecules
(antigens) on the parasite’s surface and that act directly or
cooperate with other parts of the immune system to kill
malaria parasites. The production of these ‘‘naturally
acquired’’ antibodies is initially slow so the individual can
become ill when infected. However, because the immune
system ‘‘remembers’’ how to make the antibodies, its
response to subsequent infections is quicker. The levels of
these antibodies also build up with each infection and
become more effective at killing parasites. Vaccines, which
contain malaria antigens, ‘‘prime’’ the immune system to
respond rapidly to malaria infections and produce high
concentrations of antibodies to prevent the infection from
causing serious illness.
Why Was This Study Done? A malaria vaccine that
stimulates an efficient immune response against merozoites
would limit the severity of malarial infections and prevent
many deaths but no one knows which (if any) of the antigens
on merozoites stimulate a protective immune response.
Although many different types of antibodies are produced
by the immune system, only some of these are effective in
protecting against malaria. By investigating whether there is
an association between naturally acquired antibodies, which
recognize specific candidate antigens, and protection from
malaria in populations living in areas where malaria is
endemic (always present), vaccine developers can get an
idea about which antigens to include in their vaccines.
Although many of these ‘‘malaria immuno-epidemiological
studies’’ have been undertaken, their results are somewhat
conflicting. In this study, the researchers reanalyze these
results by doing a systematic review (a study that uses
predefined criteria to identify all the research on a specific
topic) and a meta-analysis (a statistical method for
combining the results of several studies). The researchers
evaluated studies of the relationship between anti-merozoite
antibodies and the incidence (the number of new cases of a
disease in a population per year) of P. falciparum malaria in
naturally exposed populations in different regions of the
world.
What Did the Researchers Do and Find? The
researchers’ search of the published literature yielded 33
studies in which the incidence of malaria had been recorded
over time in groups of people in whom levels of antibodies
to specific merozoite antigens had been measured. These
studies measured antibodies at the start of the study and
examined the subsequent risk of malaria over several
months of follow-up (these are known as prospective
cohort studies). All but five of the studies were performed
in Africa, and very few merozoite antigens had been well-
studied in different populations, or studied at all. Of note,
very few studies had examined naturally acquired antibodies
to some leading vaccine candidates (for example, only one
study considered antibodies to MSP-142, a leading vaccine
candidate). Conversely, the association between malaria
incidence and antibodies to the antigen MSP-119, which
has been included in only one candidate vaccine, was
frequently studied. In their meta-analyses, the researchers
found that among people with antibodies to the merozoite
antigens MSP-3 (C-terminal region) and MSP-119, the risk of
developing P. falciparum malaria was reduced by 54% and
18%, respectively, compared to people without antibodies to
these antigens. There was also some evidence of a reduced
risk of malaria for people with antibodies to AMA1 and
GLURP. For other merozoite antigens, MSP1 (N-terminal
region) and MSP2, there was either weak or no evidence for a
protective effect of naturally acquired antibodies.
What Do These Findings Mean? These findings suggest
that merozoite antigens are important targets of protective
immunity in people who are naturally exposed to malaria
and also suggest which of these antigens might be included
in vaccines. However, the findings are limited by the small
number of studies identified by the researchers and
additional prospective cohort studies are clearly needed to
guide vaccine development. These studies will need to
include a larger number of lead antigens and populations
outside Africa to ensure their generalizability, note the
researchers. Furthermore, efforts will need to be made to
ensure greater consistency between studies to improve the
ability to compare results between different studies, which
was a challenge in performing this study. To this end, the
researchers propose a set of guidelines that, if followed,
should make it easier to compare the results of different
malaria immune-epidemiology studies in the future and thus
lead to better identification of candidate vaccine antigens.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000218.
N Information is available from the World Health Organiza-
tion on malaria (in several languages) and on the
development of malaria vaccines
N The US Centers for Disease Control and Prevention
provides information on malaria (in English and Spanish)
N Information is available from the Wellcome Trust on all
aspects of malaria, including vaccine development
N The Malaria Vaccine Initiative provides information on the
development of malaria vaccines and on ongoing trials
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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